Key Takeaways
- Researchers have succeeded in developing an E. coli-based “smart microbe” that secretes therapeutic payloads, including antibodies, into the gut
- In mouse models, the smart microbe was as efficacious as a systemically delivered conventional monoclonal antibody in limiting colitis in inflammatory bowel disease.
- This smart microbe has the potential to treat a variety of diseases, including intestinal infections and cancer, while limiting adverse effects that are associated with the administration of systemic drugs.
Login Or Register To Read Full Story